142 related articles for article (PubMed ID: 23424955)
1. [Expression of cytokeratins 5/6 and cytokeratin 17 in invasive breast carcinoma].
Ivković-Kapicl T; Panjković M; Nikolić I; Djilas-Ivanović D; Knezević-Usaj S
Vojnosanit Pregl; 2012 Dec; 69(12):1031-8. PubMed ID: 23424955
[TBL] [Abstract][Full Text] [Related]
2. [Expression of CK5/6 and CK17 and its correlation with prognosis of triple-negative breast cancer patients].
Liu ZB; Wu J; Ping B; Feng LQ; Shen ZZ; Shao ZM
Zhonghua Zhong Liu Za Zhi; 2008 Aug; 30(8):610-4. PubMed ID: 19102940
[TBL] [Abstract][Full Text] [Related]
3. Characteristics of basal cytokeratin expression in breast cancer.
Alshareeda AT; Soria D; Garibaldi JM; Rakha E; Nolan C; Ellis IO; Green AR
Breast Cancer Res Treat; 2013 May; 139(1):23-37. PubMed ID: 23588953
[TBL] [Abstract][Full Text] [Related]
4. Cytokeratin 5/6 fingerprinting in HER2-positive tumors identifies a poor prognosis and trastuzumab-resistant basal-HER2 subtype of breast cancer.
Martin-Castillo B; Lopez-Bonet E; Buxó M; Dorca J; Tuca-Rodríguez F; Ruano MA; Colomer R; Menendez JA
Oncotarget; 2015 Mar; 6(9):7104-22. PubMed ID: 25742793
[TBL] [Abstract][Full Text] [Related]
5. Cytokeratins 5 and 17 Maintain an Aggressive Epithelial State in Basal-Like Breast Cancer.
McGinn O; Riley D; Finlay-Schultz J; Paul KV; Kabos P; Sartorius CA
Mol Cancer Res; 2022 Sep; 20(9):1443-1455. PubMed ID: 35639459
[TBL] [Abstract][Full Text] [Related]
6. Triple negative breast cancer: a study from the point of view of basal CK5/6 and HER-1.
Pintens S; Neven P; Drijkoningen M; Van Belle V; Moerman P; Christiaens MR; Smeets A; Wildiers H; Vanden Bempt I
J Clin Pathol; 2009 Jul; 62(7):624-8. PubMed ID: 19561231
[TBL] [Abstract][Full Text] [Related]
7. Apocrine carcinoma as triple-negative breast cancer: novel definition of apocrine-type carcinoma as estrogen/progesterone receptor-negative and androgen receptor-positive invasive ductal carcinoma.
Tsutsumi Y
Jpn J Clin Oncol; 2012 May; 42(5):375-86. PubMed ID: 22450930
[TBL] [Abstract][Full Text] [Related]
8. Inference of the Basal epithelial phenotype in breast carcinoma from differential marker expression, using tissue microarrays in triple negative breast cancer and women younger than 35.
Nassar A; Sussman ZM; Lawson D; Cohen C
Breast J; 2012 Sep; 18(5):399-405. PubMed ID: 22882580
[TBL] [Abstract][Full Text] [Related]
9. [Roles of immunohistochemistry in prognostic assessment of basal-like breast cancer].
Liu H; Fan QH; Zhang ZH; Li X; Yu HP; Liu GZ; Meng FQ
Zhonghua Bing Li Xue Za Zhi; 2009 Jan; 38(1):23-8. PubMed ID: 19489221
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical co-expression status of cytokeratin 5/6, androgen receptor, and p53 as prognostic factors of adjuvant chemotherapy for triple negative breast cancer.
Maeda T; Nakanishi Y; Hirotani Y; Fuchinoue F; Enomoto K; Sakurai K; Amano S; Nemoto N
Med Mol Morphol; 2016 Mar; 49(1):11-21. PubMed ID: 26009308
[TBL] [Abstract][Full Text] [Related]
11. Clinicopathologic features of breast carcinomas classified by biomarkers and correlation with microvessel density and VEGF expression: a study from Thailand.
Chuangsuwanich T; Pongpruttipan T; O-Charoenrat P; Komoltri C; Watcharahirun S; Sa-Nguanraksa D
Asian Pac J Cancer Prev; 2014; 15(3):1187-92. PubMed ID: 24606439
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
[TBL] [Abstract][Full Text] [Related]
13. Heterogeneity of luminal breast cancer characterised by immunohistochemical expression of basal markers.
Sung H; Garcia-Closas M; Chang-Claude J; Blows FM; Ali HR; Figueroa J; Nevanlinna H; Fagerholm R; Heikkilä P; Blomqvist C; Giles GG; Milne RL; Southey MC; McLean C; Mannermaa A; Kosma VM; Kataja V; Sironen R; Couch FJ; Olson JE; Hallberg E; Olswold C; Cox A; Cross SS; Kraft P; Tamimi RM; Eliassen AH; Schmidt MK; Bolla MK; Wang Q; Easton D; Howat WJ; Coulson P; Pharoah PD; Sherman ME; Yang XR
Br J Cancer; 2016 Feb; 114(3):298-304. PubMed ID: 26679376
[TBL] [Abstract][Full Text] [Related]
14. Basal cytokeratin expression in relation to immunohistochemical and clinical characterization in breast cancer patients with triple negative phenotype.
Liu ZB; Wu J; Ping B; Feng LQ; Di GH; Lu JS; Shen KW; Shen ZZ; Shaol ZM
Tumori; 2009; 95(1):53-62. PubMed ID: 19366057
[TBL] [Abstract][Full Text] [Related]
15. Prognostic relevance of basal cytokeratin expression in operable breast cancer.
Potemski P; Kusinska R; Watala C; Pluciennik E; Bednarek AK; Kordek R
Oncology; 2005; 69(6):478-85. PubMed ID: 16410686
[TBL] [Abstract][Full Text] [Related]
16. Expression of basal and luminal cytokeratins in breast cancer and their correlation with clinicopathological prognostic variables.
Mohammadizadeh F; Naimi A; Rajabi P; Ghasemibasir H; Eftekhari A
Indian J Med Sci; 2009 Apr; 63(4):152-62. PubMed ID: 19414985
[TBL] [Abstract][Full Text] [Related]
17. [Clinicopathologic features and immunohistochemistry of the basal-like subtype of invasive breast carcinoma].
Liu LP; Bai J; Wei Y; Qi XD; Si TC; Li W; Pan H
Zhonghua Bing Li Xue Za Zhi; 2013 Feb; 42(2):101-5. PubMed ID: 23710916
[TBL] [Abstract][Full Text] [Related]
18. [Clinicopathologic study of centrally necrotizing carcinoma of breast].
Yu L; Yang WT; Cai X; Lu HF; Fan YZ; Shi DR
Zhonghua Bing Li Xue Za Zhi; 2009 Oct; 38(10):657-62. PubMed ID: 20078968
[TBL] [Abstract][Full Text] [Related]
19. The expression of cytokeratin 5/6 in invasive lobular carcinoma of the breast: evidence of a basal-like subset?
Fadare O; Wang SA; Hileeto D
Hum Pathol; 2008 Mar; 39(3):331-6. PubMed ID: 18261623
[TBL] [Abstract][Full Text] [Related]
20. Maspin expression is frequent and correlates with basal markers in triple-negative breast cancer.
Umekita Y; Ohi Y; Souda M; Rai Y; Sagara Y; Sagara Y; Tamada S; Tanimoto A
Diagn Pathol; 2011 Apr; 6():36. PubMed ID: 21496280
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]